Catalent Revenue and Competitors
Estimated Revenue & Valuation
- Catalent's estimated annual revenue is currently $4.2B per year.
- Catalent's estimated revenue per employee is $287,958
- Catalent's total funding is $550M.
- Catalent's current valuation is $18.5B. (January 2022)
Employee Data
- Catalent has 14516 Employees.
- Catalent grew their employee count by 1% last year.
Catalent Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Catalent?
Catalent Pharma Solutions, Inc. (Catalent) is a provider of advanced drug delivery and packaging technologies, and outsourced development, manufacturing, and packaging services to the global pharmaceutical and biotechnology industry. Its drug delivery and packaging technologies help its customers achieve their desired clinical and market outcomes and are used in many products. The Company’s business is organized in three segments: Oral Technologies, Sterile Technologies and Packaging Services. It has relationships with pharmaceutical and biotechnology customers. Catalent’s key customers include Pfizer, Johnson & Johnson, GlaxoSmithKline, Eli Lilly, Merck, Abbott, Genentech, Wyeth and Novartis. In March 2009, Bavaria Industriekapital AG announced that its affiliate has completed the purchase of Catalent Pharma Solutions\' Osny in France.
keywords:N/A
$550M
Total Funding
14516
Number of Employees
$4.2B
Revenue (est)
1%
Employee Growth %
$18.5B
Valuation
N/A
Accelerator
Catalent's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Regulatory Affairs and Compliance | Reveal Email/Phone |
2 | Director Labor and Employee Relations, Policy and Compliance | Reveal Email/Phone |
3 | R&D Fellow Biologics Development | Reveal Email/Phone |
4 | Senior Quality Auditor | Reveal Email/Phone |
5 | SVP, Chief Information Officer | Reveal Email/Phone |
6 | General Manager | Reveal Email/Phone |
7 | Principal Scientist, R&D | Reveal Email/Phone |
8 | Lead QA Technician - Archivist | Reveal Email/Phone |
9 | VP, Global Business Development Clinical Development and Supply | Reveal Email/Phone |
10 | Regional Sales Manager, Development and Analytical Solutions | Reveal Email/Phone |
Catalent News
Days after throwing down $350 million to beef up biologics manufacturing in Indiana, high-flying CDMO Catalent is buying a cell therapy plant on the East...
Catalent Acquires Erytech's Commercial-Scale Cell Therapy Mfg. Facility. 30,900-sq.-ft. facility in Princeton, NJ houses 16 suites for cGMP...
Catalent has acquired a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, from Erytech Pharma for $44.5m.
SOMERSET, N.J. (PRWEB) November 18, 2021 Catalent, a global leader in clinical supply services, today announced that three of its experts will be speaking on current market trends and strategies within the industry at two upcoming conferences, Outsourcing in Clinical Trials East Asia, and Outso ...